FFC#16/2021

Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease

AREA 3 Bronchopulmonary infection

FFC#16/2021

Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease
€ 0 still needed
0%
€ 104.000 goal

pRINCIPAL INVESTIGATOR

Cristina Cigana (Unità Infezioni e Fibrosi Cistica, divisione di Immunologia, Trapianti e Malattie Infettive, Istituto San Raffaele Milano)

Partner

Daniela Girelli (Lab. Microbiologia FC, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano); Ersilia Vita Fiscarelli (Lab. Microbiologia FC, Ospedale Bambino Gesù, Roma)

Researchers

12

Category

AREA 3 Bronchopulmonary infection

Duration

2 years

Goal

€ 104.000

Funds raised

€ 104.000

Objectives

Recent experimental data suggest that new therapies, such as Kaftrio (Trikafta) and modulators in general, also have activities independent from those exercised on CFTR. The aim of the project is to define whether, how and to what extent Kaftrio affects the susceptibility to antibiotics and the virulence of P. aeruginosa. The researchers aim to define the anti-bacterial effects of Kaftrio and to identify specific strains of P. aeruginosa that may represent a risk factor for the efficacy of this drug. The results obtained could generate recommendations for the use of Kaftrio, also in combination with antibiotic treatment, to optimally transfer the results to the clinical setting.


XIX Convention FFC Ricerca – download here a brief presentation of the project

WHO ADOPTED THE PROJECT

Delegazione FFC Ricerca di Roma Vaticano

€ 20.000

Delegazione FFC Ricerca di Napoli

€ 10.000

Delegazione FFC Ricerca di Moncalvo

€ 35.000

Delegazione FFC Ricerca di Vittoria Ragusa Siracusa

€ 19.500

Delegazione FFC Ricerca di Catania Mascalucia

€ 19.500

Delegazione FFC Ricerca di Moncalvo

€ 35.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches